Mumbai, March 31 -- The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the...